<![CDATA[Embla Medical — Oktober 2024]]>Velkommen til Embla Medical chat.

]]>https://dev.proinvestor.com/forum/topic/401339/embla-medical-oktober-2024RSS for NodeSat, 06 Jun 2026 06:05:13 GMTThu, 17 Oct 2024 11:37:11 GMT60<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 29 Oct 2024 04:15:37 GMT]]>BSinvest..Bruno Japp fra ØU har den samme analyse og kursmål, som du på aktien. I er begge af den gamle skole. 😉

]]>https://dev.proinvestor.com/forum/post/8056366https://dev.proinvestor.com/forum/post/8056366Tue, 29 Oct 2024 04:15:37 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Mon, 28 Oct 2024 10:42:55 GMT]]>"Embla sikker havn ved rødt efterår på aktiemarkedet
Embla Medicals

  1. kvartalsregnskab bekræftede investorernes positive syn på selskabet og aktien. På kort sigt forstærkes det positive syn på aktien af, at kursen med en betaværdi på 0,17 er stort set immun overfor en generel nedtur på aktiemarkedet".

Læs hele analysen fra Økonomisk Ugebrev i debatten: https://proinvestor.com/boards/122728/

]]>https://dev.proinvestor.com/forum/post/8056364https://dev.proinvestor.com/forum/post/8056364Mon, 28 Oct 2024 10:42:55 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Fri, 25 Oct 2024 13:07:57 GMT]]>Selvom regnskabssæsonen ikke for alvor er gået i gang endnu, er der endnu en gang besøgsrekord på ProInvestor.com. Tak for at følge med! I denne pharma- og biotekopdatering kommer Helge Larsen ind på fedmesektoren, bl.a. et nyt studie fra Novo, hvor glp1 i Ozempic kan have en positiv effekt på alzheimers. Slutteligt fortæller han om Embla Medical, som laver proteser, og hvor nyeste skud på stammen er udviklet med kunstig intelligens. Kort video https://proinvestor.com/boards/122728

]]>https://dev.proinvestor.com/forum/post/8056365https://dev.proinvestor.com/forum/post/8056365Fri, 25 Oct 2024 13:07:57 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Thu, 24 Oct 2024 06:44:08 GMT]]>Handles på en p/e på 33,5. Det er vel et fair niveau med de kortsigtede vækstudsigter. Får bionik-proteserne for alvor et gennembrud vil kursen ryge gevaldigt i vejret. Det bliver spændende at følge.

]]>https://dev.proinvestor.com/forum/post/8056363https://dev.proinvestor.com/forum/post/8056363Thu, 24 Oct 2024 06:44:08 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Thu, 24 Oct 2024 06:32:31 GMT]]>Likviditeten er ikke særlig stor i Embla. Svært at samle en større portion op uden at aktien stiger for meget.

]]>https://dev.proinvestor.com/forum/post/8056359https://dev.proinvestor.com/forum/post/8056359Thu, 24 Oct 2024 06:32:31 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Thu, 24 Oct 2024 03:09:56 GMT]]>Embla Medical – Recording of Q3 2024 result presentation https://www.inderes.dk/analyst-comments/embla-medical-recording-of-q3-2024-result-presentation?utm_source=nordnet&utm_medium=integration

]]>https://dev.proinvestor.com/forum/post/8056361https://dev.proinvestor.com/forum/post/8056361Thu, 24 Oct 2024 03:09:56 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Wed, 23 Oct 2024 05:20:00 GMT]]>HCAs event i dag - Embla Medical – Presentation of Interim report Q3 2024 https://www.inderes.dk/videos/embla-medical-presentation-of-interim-report-q3-2024

]]>https://dev.proinvestor.com/forum/post/8056367https://dev.proinvestor.com/forum/post/8056367Wed, 23 Oct 2024 05:20:00 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Wed, 23 Oct 2024 05:18:19 GMT]]>Embla Medical får hævet kursmålet til 41 kr. fra 36,40 kr. hos Nordea https://proinvestor.com/investornyt/1231187/embla-medical-far-haevet-kursmalet-til-41-kr-fra-3640-kr-hos-nordea

]]>https://dev.proinvestor.com/forum/post/8056362https://dev.proinvestor.com/forum/post/8056362Wed, 23 Oct 2024 05:18:19 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:47:19 GMT]]>To actively participate in the Q&A session of the call please use following link for dial in options https://register.vevent.com/register/BI0f67d9e43c4f4ff484123ef1cff5e472

]]>https://dev.proinvestor.com/forum/post/8056358https://dev.proinvestor.com/forum/post/8056358Tue, 22 Oct 2024 04:47:19 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:45:55 GMT]]>Konference call: https://edge.media-server.com/mmc/p/o2dxucfe/

]]>https://dev.proinvestor.com/forum/post/8056360https://dev.proinvestor.com/forum/post/8056360Tue, 22 Oct 2024 04:45:55 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:43:40 GMT]]>Turnarounden efter nogle dårlige år må siges at være mere end godkendt. 🙂

]]>https://dev.proinvestor.com/forum/post/8056356https://dev.proinvestor.com/forum/post/8056356Tue, 22 Oct 2024 04:43:40 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:36:30 GMT]]>Positivt med fremgang på alle markeder.

]]>https://dev.proinvestor.com/forum/post/8056354https://dev.proinvestor.com/forum/post/8056354Tue, 22 Oct 2024 04:36:30 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:34:28 GMT]]>Et stærkt regnskab helt som forventet.

]]>https://dev.proinvestor.com/forum/post/8056357https://dev.proinvestor.com/forum/post/8056357Tue, 22 Oct 2024 04:34:28 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:14:42 GMT]]>Embla Medical ser frem mod udvidet dækning i USA efter stærkt tredje kvartal https://proinvestor.com/investornyt/1230517/embla-medical-ser-frem-mod-udvidet-daekning-i-usa-efter-staerkt-tredje-kvartal

]]>https://dev.proinvestor.com/forum/post/8056351https://dev.proinvestor.com/forum/post/8056351Tue, 22 Oct 2024 04:14:42 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:13:08 GMT]]>Medwatch: Embla Medical vokser encifret i tredje kvartal
Den islandske proteseproducent kan se frem til udvidet dækning i USA. https://medwatch.dk/Medico___Rehab/article17560107.ece

]]>https://dev.proinvestor.com/forum/post/8056353https://dev.proinvestor.com/forum/post/8056353Tue, 22 Oct 2024 04:13:08 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:09:40 GMT]]>Læs hele meddelelsen: https://mb.cision.com/Main/18404/4054217/3065335.pdf

]]>https://dev.proinvestor.com/forum/post/8056350https://dev.proinvestor.com/forum/post/8056350Tue, 22 Oct 2024 04:09:40 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:09:01 GMT]]>2024 outlook

We reiterate our full year guidance of 6-8% organic sales growth and ~20% EBITDA margin before special items.

]]>https://dev.proinvestor.com/forum/post/8056352https://dev.proinvestor.com/forum/post/8056352Tue, 22 Oct 2024 04:09:01 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:08:42 GMT]]>A global team of elite para-athletes who wear Össur’s renowned prosthetics won 22 medals and set five new Paralympic Records during the 2024 Paralympic Games in Paris, with the company’s iconic carbon fiber Cheetah sports blades, easily identifiable by their distinctive yellow stripe, dominating several categories of Athletics competition

]]>https://dev.proinvestor.com/forum/post/8056355https://dev.proinvestor.com/forum/post/8056355Tue, 22 Oct 2024 04:08:42 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:08:25 GMT]]>Other highlights

During the third quarter we introduced the third generation of our Naked Prosthetics finger device portfolio, while our newly launched bionic knee solutions, NAVii® by Össur and Icon® by College Park continue to be rolled out in selected markets as part of our limited launch program. A full launch of NAVii and Icon is expected early 2025, as previously announced.

]]>https://dev.proinvestor.com/forum/post/8056346https://dev.proinvestor.com/forum/post/8056346Tue, 22 Oct 2024 04:08:25 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:07:47 GMT]]>Net profit grew by 58% and was USD 22 million with a net profit margin of 10%, compared to 7% of sales in Q3 2023.
Cash generated from operations amounted to USD 52 million or 24% of sales, compared to 17% of sales in Q3 2023.
Free cash flow amounted to USD 33 million or 15% of sales, compared to 9% of sales in Q3 2023. Free cash flow was strong in the third quarter with solid operating results.
NIBD/EBITDA before special items was 2.8x at the end of Q3 2024. Share buybacks continue to be pause

]]>https://dev.proinvestor.com/forum/post/8056347https://dev.proinvestor.com/forum/post/8056347Tue, 22 Oct 2024 04:07:47 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:06:53 GMT]]>Gross profit margin was 63%, compared to 62% in Q3 2023. The increase in gross profit can partly be ascribed to cost reduction initiatives in manufacturing implemented during Q1 as well as better product mix and manufacturing efficiency.
EBITDA amounted to USD 47 million, and EBITDA margin was 22% of sales, compared to 19% in Q3 2023. Increasing gross profit margin and continued cost control contributed to increased profitability

]]>https://dev.proinvestor.com/forum/post/8056349https://dev.proinvestor.com/forum/post/8056349Tue, 22 Oct 2024 04:06:53 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:06:40 GMT]]>Highlights Q3 2024

Sales amounted to USD 214 million and organic growth was 7%, compared to 7% in Q3 2023. In local currency sales growth was 10% increase including acquisitions and 11% reported growth (USD growth).
Prosthetics & Neuro Orthotics sales grew by 9%, Patient Care grew 9%, while Bracing & Supports grew by 1% (all organically). EMEA continued to contribute strongly during Q3, whereas performance in Americas remained soft. APAC delivered good growth.

]]>https://dev.proinvestor.com/forum/post/8056345https://dev.proinvestor.com/forum/post/8056345Tue, 22 Oct 2024 04:06:40 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:05:43 GMT]]>Our EBITDA margin came in strong for the quarter at 22%. We continue to see the positive effects from the cost reduction initiatives implemented in manufacturing earlier this year as well as contribution from better product mix and cost control.

We are executing well on our Growth’27 strategy and reiterate our full year guidance of 6-8% organic sales growth and ~20% EBITDA margin before special items.”

]]>https://dev.proinvestor.com/forum/post/8056348https://dev.proinvestor.com/forum/post/8056348Tue, 22 Oct 2024 04:05:43 GMT<![CDATA[Reply to Embla Medical — Oktober 2024 on Tue, 22 Oct 2024 04:05:23 GMT]]>As of September 1, 2024, US Medicare has expanded access to advanced bionics for K2 patients. Healthcare professionals are currently assessing first patients as part of the replacement cycle through medical documentation that a bionic knee would improve the patient’s functional health outcomes.

]]>https://dev.proinvestor.com/forum/post/8056343https://dev.proinvestor.com/forum/post/8056343Tue, 22 Oct 2024 04:05:23 GMT